产品
编 号：F116999
分子式：C29H48N12O12S2
分子量：820.89
分子式：C29H48N12O12S2
分子量：820.89
产品类型
规格
价格
是否有货
结构图
CAS No: 1313004-77-1
产品详情
生物活性：
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.
体内研究：
LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines.Animal Model:Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)
Dosage:100 μg/kg
Administration:Intravenous injection
Result:Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.
体外研究：
LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells.LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery. LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand.
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.
体内研究：
LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines.Animal Model:Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)
Dosage:100 μg/kg
Administration:Intravenous injection
Result:Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.
体外研究：
LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells.LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery. LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备